Edwards Lifesciences Corp (EW)vsNovocure Ltd (NVCR)
EW
Edwards Lifesciences Corp
$85.96
-1.70%
HEALTHCARE · Cap: $49.01B
NVCR
Novocure Ltd
$17.16
-4.61%
HEALTHCARE · Cap: $2.06B
Smart Verdict
WallStSmart Research — data-driven comparison
Edwards Lifesciences Corp generates 835% more annual revenue ($6.30B vs $674.41M). EW leads profitability with a 17.4% profit margin vs -25.7%. EW earns a higher WallStSmart Score of 61/100 (C+).
EW
Buy61
out of 100
Grade: C+
NVCR
Avoid29
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+68.7%
Fair Value
$253.29
Current Price
$85.96
$167.33 discount
Margin of Safety
+81.5%
Fair Value
$56.90
Current Price
$17.16
$39.74 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Strong operational efficiency at 31.2%
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
16.7% revenue growth
No standout strengths identified
Areas to Watch
Expensive relative to growth rate
Weak financial health signals
Premium valuation, high expectations priced in
Negative free cash flow — burning cash
Weak financial health signals
ROE of -52.3% — below average capital efficiency
Earnings declined 6.0%
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : EW
The strongest argument for EW centers on Operating Margin, Debt/Equity, Altman Z-Score. Profitability is solid with margins at 17.4% and operating margin at 31.2%. Revenue growth of 16.7% demonstrates continued momentum.
Bull Case : NVCR
Revenue growth of 12.3% demonstrates continued momentum.
Bear Case : EW
The primary concerns for EW are PEG Ratio, Piotroski F-Score, P/E Ratio. A P/E of 46.0x leaves little room for execution misses.
Bear Case : NVCR
The primary concerns for NVCR are Piotroski F-Score, Return on Equity, EPS Growth.
Key Dynamics to Monitor
EW profiles as a growth stock while NVCR is a turnaround play — different risk/reward profiles.
NVCR carries more volatility with a beta of 0.92 — expect wider price swings.
EW is growing revenue faster at 16.7% — sustainability is the question.
NVCR generates stronger free cash flow (-19M), providing more financial flexibility.
Bottom Line
EW scores higher overall (61/100 vs 29/100), backed by strong 17.4% margins and 16.7% revenue growth. NVCR offers better value entry with a 81.5% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Edwards Lifesciences Corp
HEALTHCARE · MEDICAL DEVICES · USA
Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring.
Visit Website →Novocure Ltd
HEALTHCARE · MEDICAL DEVICES · USA
NovoCure Limited, an oncology company, is engaged in the development, manufacture and marketing of Optune for the treatment of a variety of solid tumors. The company is headquartered in Saint Helier, Jersey.
Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?